Recurrence‐free survival rates after external‐beam radiotherapy for patients with clinical T1–T3 prostate carcinoma in the prostate‐specific antigen era

The objective of the current study was to report biochemical recurrence–free survival (bRFS) rates among men with T1–T3 prostate carcinoma who were treated with external‐beam radiotherapy (RT) at the Cleveland Clinic Foundation (Cleveland, OH).

[1]  C. Reddy,et al.  Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome. , 2003, International journal of radiation oncology, biology, physics.

[2]  A. Hanlon,et al.  The Gleason score shift: score four and seven years ago. , 2003, International journal of radiation oncology, biology, physics.

[3]  E. Horwitz.  Conformal radiotherapy with dose escalation appears safe and effective in localised prostate cancer. , 2003, Cancer treatment reviews.

[4]  George Starkschall,et al.  Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. , 2002, International journal of radiation oncology, biology, physics.

[5]  J. Manola,et al.  Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. , 2002, International journal of radiation oncology, biology, physics.

[6]  Michael J. Zelefsky,et al.  High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. , 2002, International journal of radiation oncology, biology, physics.

[7]  Patrick A Kupelian,et al.  Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[8]  M. Zelefsky,et al.  Intensity-modulated radiation therapy for prostate cancer. , 2002, Seminars in radiation oncology.

[9]  Alexandra L Hanlon,et al.  Dose response in prostate cancer with 8-12 years' follow-up. , 2001, International journal of radiation oncology, biology, physics.

[10]  C. Reddy,et al.  Dose/Volume Relationship of Late Rectal Bleeding After External Beam Radiotherapy for Localized Prostate Cancer: Absolute or Relative Rectal Volume? , 2001, Cancer journal.

[11]  P. Kupelian,et al.  Short-course, intensity-modulated radiotherapy for localized prostate cancer. , 2001, Cancer journal.

[12]  D. Hussey.  American Society for Therapeutic Radiology and Oncology , 2001 .

[13]  A. Renshaw,et al.  Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. , 2000, JAMA.

[14]  A. V. von Eschenbach,et al.  External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. , 2000, International journal of radiation oncology, biology, physics.

[15]  A. Hanlon,et al.  Defining the appropriate radiation dose for pretreatment PSA < or = 10 ng/mL prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[16]  C. Reddy,et al.  Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[17]  T R Willoughby,et al.  Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland. , 2000, International journal of radiation oncology, biology, physics.

[18]  H. Levin,et al.  Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[20]  G J Kutcher,et al.  Three-dimensional conformal radiotherapy and dose escalation: where do we stand? , 1998, Seminars in radiation oncology.

[21]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[22]  E. Klein,et al.  Indications for excluding the seminal vesicles when treating clinically localized prostatic adenocarcinoma with radiotherapy alone. , 1997, International Journal of Radiation Oncology, Biology, Physics.

[23]  G Starkschall,et al.  Conventional vs. conformal radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. , 1996, International journal of radiation oncology, biology, physics.

[24]  C. Reddy,et al.  Localized prostate cancer treated with radiotherapy: who benefits from hormonal therapy? , 2000 .

[25]  C. Reddy,et al.  Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. , 2000, Urology.